Singapore, April 1 -- Japan-headquartered Daiichi Sankyo, the global healthcare company, launched its subsidiary Daiichi Sankyo Singapore Pte. Ltd. to bridge unmet needs in oncology. The Singapore subsidiary will be home to the regional hub of RDPV QA (Research & Development, Pharmacovigilance, and Quality Assurance) function, serving as a centre of excellence for key processes and systems across the region.". In addition, the Singapore subsidiary will focus on antibody-drug conjugates (ADCs), a class of drugs that offer targeted precision and potent drug delivery to certain tumour types. ADCs deliver potent cancer-killing agents directly to cancer cells to eliminate them, whilst limiting damage to healthy surrounding cells. Koichi Morino...